Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick injury. Its development programs are oral tablet vaccines designed to protect against norovirus, seasonal influenza and respiratory syncytial virus, as well as a therapeutic vaccine for human papillomavirus. Vaxart, Inc., formerly known as Aviragen Therapeutics, is based in South San Francisco, United States.
| Revenue (Most Recent Fiscal Year) | $237.26M |
| Net Income (Most Recent Fiscal Year) | $16.33M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 4.13 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.59 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 6.05 |
| Pre-Tax Margin (Trailing 12 Months) | 14.67% |
| Net Margin (Trailing 12 Months) | 14.51% |
| Return on Equity (Trailing 12 Months) | 61.43% |
| Return on Assets (Trailing 12 Months) | 20.07% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.37 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.02 |
| Earnings per Share (Most Recent Fiscal Year) | $0.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.15 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 242.04M |
| Free Float | 235.27M |
| Market Capitalization | $150.07M |
| Average Volume (Last 20 Days) | 0.43M |
| Beta (Past 60 Months) | 1.10 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 18.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |